No products in the cart.
Pre-made Avdoralimab benchmark antibody ( Whole mAb, anti-C5AR1 therapeutic antibody, Anti-C5AR/C5R1/CD88 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-039
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Avdoralimab (IPH 5401, formerly NN 8210) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody, being developed by Innate Pharma, for the treatment of solid tumours, chronic spontaneous urticaria [chronic urticaria in development table], Bullous-pemphigoid and COVID-19 pneumonia.
| Products Name (INN Index) | Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody |
|---|---|
| INN Name | Avdoralimab |
| Target | C5ar1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Novo Nordisk,Innate Pharma |
| Conditions Approved | NA |
| Conditions Active | Bullous pemphigoid,COVID-19,Urticaria,Liver cancer,Non-small cell lung cancer,Solid tumours |
| Conditions Discontinued | Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | C5AR1 |
| Package |
Previous slide
Next slide
